117 related articles for article (PubMed ID: 8625674)
1. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
Hunt KJ; Longton G; Williams MA; Livingston RB
Chest; 1996 May; 109(5):1239-42. PubMed ID: 8625674
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
3. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
Andreopoulou E; Ross PJ; O'Brien ME; Ford HE; Priest K; Eisen T; Norton A; Ashley S; Smith IE
Ann Oncol; 2004 Sep; 15(9):1406-12. PubMed ID: 15319247
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
Tsavaris N; Mylonakis N; Karvounis N; Bacoyiannis C; Briasoulis E; Skarlos D; Pavlidis N; Stamatelos G; Kosmidis P
Lung Cancer; 1994 Sep; 11(3-4):299-303. PubMed ID: 7812707
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
Byrne MJ; Davidson JA; Musk AW; Dewar J; van Hazel G; Buck M; de Klerk NH; Robinson BW
J Clin Oncol; 1999 Jan; 17(1):25-30. PubMed ID: 10458214
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
Metintas M; Ozdemir N; Uçgun I; Elbek O; Kolsuz M; Mutlu S; Metintas S
Chest; 1999 Aug; 116(2):391-8. PubMed ID: 10453867
[TBL] [Abstract][Full Text] [Related]
9. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
11. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
O'Brien ME; Watkins D; Ryan C; Priest K; Corbishley C; Norton A; Ashley S; Rowell N; Sayer R
Ann Oncol; 2006 Feb; 17(2):270-5. PubMed ID: 16317014
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
13. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Knuuttila A; Ollikainen T; Halme M; Mali P; Kivisaari L; Linnainmaa K; Jekunen A; Mattson K
Anticancer Drugs; 2000 Apr; 11(4):257-61. PubMed ID: 10898540
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.
Arrieta Ó; Medina LA; Estrada-Lobato E; Hernández-Pedro N; Villanueva-Rodríguez G; Martínez-Barrera L; Macedo EO; López-Rodríguez V; Motola-Kuba D; Corona-Cruz JF
Br J Cancer; 2012 Mar; 106(6):1027-32. PubMed ID: 22353806
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
